HCA Healthcare heads into its third-quarter report with a stock that has rallied hard since management cut its full-year outlook, which is an unusual reaction to a guidance reduction. The explanation lies in what the market chose to believe last quarter: that the expiration of enhanced premium tax credits had been fully reckoned with, and that underlying insured demand and cost discipline could carry the rest of the year. The October 27 release, due before the opening bell, is the first real check on whether that judgment was right.
The Street is bracing for a modest step back. Consensus calls for earnings of $6.75 a share, about 3% below the $6.96 earned a year ago, on revenue of roughly $19.38 billion, up just 1.1%. The Earnings Whisper sits at $6.83, a touch above consensus, hinting that the bar is a little higher than published estimates without suggesting anyone expects a blowout. The sequential drop from the second quarter's $7.59 looks steep, but that figure was flattered by the Florida Medicaid directed payment program, which delivered a $540 million net benefit including 21 months of catch-up. Stripping that out, a softer third quarter is largely by design, and management also flagged a $100 million to $300 million back-half supplemental headwind as prior-year approvals roll off.
On the full year, HCA reaffirmed earnings guidance of $28.70 to $30.50 a share and revenue of $77 billion to $79.5 billion. Analysts at $29.19 a share sit in the lower half of the earnings range, while their $78.47 billion revenue estimate lands slightly above the midpoint. That combination signals skepticism about margins more than volume, which fits the story from last quarter. The exchange headwind ballooned to $1.0 billion to $1.2 billion of EBITDA from the $600 million to $900 million management had defended for two straight quarters, because nearly every lapsed exchange enrollee became uninsured and kept using care at roughly the same rate. Having already widened that estimate once, HCA cannot afford a second revision. Exchange adjusted admissions fell 15% in both the first and second quarters; stability around that level would validate the new framework, while further erosion or a heavier uninsured mix would challenge it.
The offsets matter just as much. Insured admissions outside the exchanges accelerated to 3.2% growth in the second quarter, and same-facility cost per equivalent admission was essentially flat year over year, evidence that the roughly $400 million resiliency program is working. Continued strength in both would support the case that HCA can grow back toward its long-term 4% to 6% EBITDA algorithm. The weak spot is surgery. Inpatient procedures fell 2.3% and outpatient 3.4% in the second quarter, worse than the first, with elective inpatient cases down 6% year to date as physicians cited broad affordability strain. Another sequential slide would suggest consumer pressure is spreading beyond the exchange population, a more troubling development than a policy-driven hit. Commentary on the Texas Medicaid conversion slowdown and the 2027 work requirement overhang will also shape how investors model next year.
Expectations have warmed considerably. Sentiment remains on the bearish side but is far less negative than the deeply pessimistic reading heading into the last report, and the shares have gained about 20% since then against roughly 3% for the S&P 500. At about $459, the stock trades above its 200-day moving average near $445 and in the upper part of its post-earnings range, though still about 4% shy of the $478.86 high. That rally means the easy relief trade is spent.
The central question is whether the exchange damage has stopped growing. If HCA holds its EBITDA range, keeps costs flat and shows surgical volumes stabilizing, management's promise that fourth-quarter growth will outpace the third becomes credible. If the uninsured drag widens again or electives keep sliding, the recent rally will look premature.